'Quadrapeutics' Shows Promise in Preclinical Study of Hard-to-Treat Tumors

A novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells without harming surrounding normal organs.

A novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells without harming surrounding normal organs, the maiden preclinical study of a new Rice University-developed anti-cancer technology revealed.

The research, which is available online this week Nature Medicine, reports that Rice's "quadrapeutics" technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.

Tumor Markers - For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive results.

The work was conducted by researchers from Rice, the University of Texas MD Anderson Cancer Center and Northeastern University.

"We address aggressive cancers that cannot be efficiently and safely treated today," said Rice scientist Dmitri Lapotko, the study's lead investigator. "Surgeons often cannot fully remove tumors that are intertwined with important organs. Chemotherapy and radiation are commonly used to treat the residual portions of these tumors, but some tumors become resistant to chemoradiation. Quadrapeutics steps up when standard treatments fail. At the same time, quadrapeutics complements current approaches instead of replacing them."

Lapotko said quadrapeutics differs from other developmental cancer treatments in that it radically amplifies the intracellular effect of drugs and radiation only in cancer cells. The quadrapeutic effects are achieved by mechanical events -- tiny, remotely triggered nano-explosions called "plasmonic nanobubbles." Plasmonic nanobubbles are non-stationary vapors that expand and burst inside cancer cells in nanoseconds in response to a short, low-energy laser pulse. Plasmonic nanobubbles act as a "mechanical drug" against cancer cells that cannot be surgically removed and are otherwise resistant to radiation and chemotherapy.

About Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors account for about 2.4% of all the tumor diagnosesandare most challenging due to their critically delicate location.

In prior studies, Lapotko showed he could use plasmonic nanobubbles alone to literally blow cells apart. In quadrapeutics, his team is using them to detect and kill cancer cells in three ways. In cancer cells that survive the initial explosions, the bursting nanobubbles greatly magnify the local doses of both chemotherapy drugs and radiation. All three effects -- mechanical cell destruction, intracellular drug ejection and radiation amplification -- occur only in cancer cells and do not harm vital healthy cells nearby.

To administer quadrapeutics, the team uses four clinically approved components: chemotherapy drugs, radiation, near-infrared laser pulses of low energy and colloidal gold.

Auditory Tumor - Causes Symptoms Diagnosis Treatment Prognosis Complications
Auditory Tumor or Acoustic neuroma is a benign growth that arises on the vestibular cochlear nerve. It is not a cancer. Read more on the causes, symptoms, diagnosis and treatment.

"Quadrapeutics shifts the therapeutic paradigm for cancer from materials -- drugs or nanoparticles -- to mechanical events that are triggered on demand only inside cancer cells," Lapotko said. "Another strategic innovation is in complementing current macrotherapies with microtreatment. We literally bring surgery, chemotherapies and radiation therapies inside cancer cells."

The first component of quadrapeutics is a low dose of a clinically validated chemotherapy drug. The team tested two: doxorubicin and paclitaxel. In each case, the scientists used encapsulated versions of the drug that were tagged with antibodies designed to target cancer cells. Thanks to the magnifying effect of the plasmonic nanobubbles, the intracellular dose -- the amount of the drug that is active inside cancer cells -- is very high even when the patient receives only a few percent of the typical clinical dose.

Carcinoid Tumors - Carcinoid Syndrome - Symptoms, Signs, Diagnosis & Treatment
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all carcinoid tumors are associated with the carcinoid syndrome.

The second component is an injectable solution of nontoxic gold colloids, tiny spheres of gold that are thousands of times smaller than a living cell. Quadrapeutics represents a new use of colloidal gold, which has been used for decades in the clinical treatment of arthritis. In quadrapeutics, the gold colloids are tagged with cancer-specific clinically approved antibodies that cause them to accumulate and cluster together inside cancer cells. These gold "nanoclusters" do nothing until activated by a laser pulse or radiation.

The third quadrapeutic component is a short near-infrared laser pulse that uses 1 million times less energy that a typical surgical laser. A standard endoscope delivers the laser pulse to the tumor, where the gold nanoclusters convert the laser energy into plasmonic nanobubbles.

Source-Eurekalert